StemCells (STEM) Begins Phase II Pathway Study of HuCNS-SC in Cervical Spinal Cord Injury
Tweet Send to a Friend
StemCells, Inc. (Nasdaq: STEM) announced today that it has initiated its Pathway® Study, a Phase II proof of concept clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
